B-intervention	0	8	Axillary
I-intervention	9	19	dissection
O	20	26	versus
B-control	27	29	no
I-control	30	38	axillary
I-control	39	49	dissection
O	50	52	in
B-eligibility	53	60	elderly
I-eligibility	61	69	patients
I-eligibility	70	74	with
I-eligibility	75	81	breast
I-eligibility	82	88	cancer
I-eligibility	89	92	and
I-eligibility	93	95	no
I-eligibility	96	104	palpable
I-eligibility	105	113	axillary
I-eligibility	114	119	nodes
O	119	120	:
O	121	128	results
O	129	134	after
O	135	137	15
O	138	143	years
O	144	146	of
O	147	153	follow
O	153	154	-
O	154	156	up
O	156	157	.

O	158	160	To
O	161	167	assess
O	168	171	the
O	172	176	long
O	176	177	-
O	177	181	term
O	182	188	safety
O	189	191	of
O	192	194	no
O	195	203	axillary
O	204	213	clearance
O	214	216	in
O	217	224	elderly
O	225	233	patients
O	234	238	with
O	239	245	breast
O	246	252	cancer
O	253	256	and
O	257	268	nonpalpable
O	269	277	axillary
O	278	283	nodes
O	283	284	.

O	285	290	Lymph
O	291	295	node
O	296	306	evaluation
O	307	309	in
O	310	317	elderly
O	318	326	patients
O	327	331	with
O	332	337	early
O	338	344	breast
O	345	351	cancer
O	352	355	and
O	356	366	clinically
O	367	375	negative
O	376	384	axillary
O	385	390	nodes
O	391	393	is
O	394	407	controversial
O	407	408	.

O	409	412	Our
O	413	423	randomized
O	424	429	trial
O	430	434	with
O	435	436	5
O	436	437	-
O	437	441	year
O	442	448	follow
O	448	449	-
O	449	451	up
O	452	458	showed
O	459	461	no
O	462	468	breast
O	469	475	cancer
O	476	485	mortality
O	486	495	advantage
O	496	499	for
O	500	508	axillary
O	509	518	clearance
O	519	527	compared
O	528	532	with
O	533	544	observation
O	545	547	in
O	548	553	older
O	554	562	patients
O	563	567	with
O	568	572	T1N0
O	573	580	disease
O	580	581	.

O	582	584	We
O	585	592	further
O	593	605	investigated
O	606	614	axillary
O	615	624	treatment
O	625	627	in
O	628	629	a
O	630	643	retrospective
O	644	652	analysis
O	653	655	of
B-total-participants	656	659	671
O	660	671	consecutive
O	672	680	patients
O	680	681	,
O	682	686	aged
B-age	687	688	â‰¥
I-age	689	691	70
I-age	692	697	years
O	697	698	,
B-eligibility	699	703	with
I-eligibility	704	712	operable
I-eligibility	713	719	breast
I-eligibility	720	726	cancer
I-eligibility	727	730	and
I-eligibility	731	732	a
I-eligibility	733	743	clinically
I-eligibility	744	749	clear
I-eligibility	750	756	axilla
O	756	757	,
O	758	765	treated
O	766	773	between
O	774	778	1987
O	779	782	and
O	783	787	1992
O	787	788	;
O	789	792	172
O	793	801	received
O	802	805	and
O	806	809	499
O	810	813	did
O	814	817	not
O	818	825	receive
O	826	834	axillary
O	835	845	dissection
O	845	846	;
O	847	849	20
O	850	852	mg
O	852	853	/
O	853	856	day
O	857	866	tamoxifen
O	867	870	was
O	871	881	prescribed
O	882	885	for
O	886	888	at
O	889	894	least
O	895	896	2
O	897	902	years
O	902	903	.

O	904	906	We
O	907	911	used
O	912	925	multivariable
O	926	934	analysis
O	935	937	to
O	938	942	take
O	943	950	account
O	951	953	of
O	954	957	the
O	958	962	lack
O	963	965	of
O	966	979	randomization
O	979	980	.

O	981	986	After
O	987	993	median
O	994	1000	follow
O	1000	1001	-
O	1001	1003	up
O	1004	1006	of
O	1007	1009	15
O	1010	1015	years
O	1016	1017	(
O	1017	1030	interquartile
O	1031	1036	range
O	1037	1039	14
O	1039	1040	-
O	1040	1042	17
O	1043	1048	years
O	1048	1049	)
O	1050	1055	there
O	1056	1059	was
O	1060	1062	no
O	1063	1074	significant
O	1075	1085	difference
O	1086	1088	in
B-outcome	1089	1095	breast
I-outcome	1096	1102	cancer
I-outcome	1103	1112	mortality
O	1113	1120	between
O	1121	1124	the
O	1125	1133	axillary
O	1134	1137	and
O	1138	1140	no
O	1141	1149	axillary
O	1150	1159	clearance
O	1160	1166	groups
O	1166	1167	.

O	1168	1173	Crude
O	1174	1184	cumulative
B-outcome	1185	1187	15
I-outcome	1187	1188	-
I-outcome	1188	1192	year
I-outcome	1193	1202	incidence
I-outcome	1203	1205	of
I-outcome	1206	1214	axillary
I-outcome	1215	1222	disease
O	1223	1225	in
O	1226	1229	the
O	1230	1232	no
O	1233	1241	axillary
O	1242	1252	dissection
O	1253	1258	group
O	1259	1262	was
O	1263	1266	low
O	1266	1267	:
B-iv-bin-percent	1268	1269	5
I-iv-bin-percent	1269	1270	.
I-iv-bin-percent	1270	1271	8
I-iv-bin-percent	1271	1272	%
O	1273	1280	overall
O	1281	1284	and
B-iv-bin-percent	1285	1286	3
I-iv-bin-percent	1286	1287	.
I-iv-bin-percent	1287	1288	7
I-iv-bin-percent	1288	1289	%
O	1290	1293	for
O	1294	1297	pT1
O	1298	1306	patients
O	1306	1307	.

O	1308	1315	Elderly
O	1316	1324	patients
O	1325	1329	with
O	1330	1335	early
O	1336	1342	breast
O	1343	1349	cancer
O	1350	1353	and
O	1354	1364	clinically
O	1365	1373	negative
O	1374	1379	nodes
O	1380	1383	did
O	1384	1387	not
O	1388	1395	benefit
O	1396	1398	in
O	1399	1404	terms
O	1405	1407	of
O	1408	1414	breast
O	1415	1421	cancer
O	1422	1431	mortality
O	1432	1436	from
O	1437	1446	immediate
O	1447	1455	axillary
O	1456	1466	dissection
O	1467	1469	in
O	1470	1474	this
O	1475	1488	nonrandomized
O	1489	1494	study
O	1494	1495	.

O	1496	1504	Sentinel
O	1505	1509	node
O	1510	1516	biopsy
O	1517	1522	could
O	1523	1527	also
O	1528	1530	be
O	1531	1539	foregone
O	1540	1543	due
O	1544	1546	to
O	1547	1550	the
O	1551	1555	very
O	1556	1559	low
O	1560	1570	cumulative
O	1571	1580	incidence
O	1581	1583	of
O	1584	1592	axillary
O	1593	1600	disease
O	1601	1603	in
O	1604	1608	this
O	1609	1612	age
O	1613	1618	group
O	1618	1619	.

O	1620	1628	Axillary
O	1629	1639	dissection
O	1640	1646	should
O	1647	1649	be
O	1650	1660	restricted
O	1661	1663	to
O	1664	1667	the
O	1668	1673	small
O	1674	1680	number
O	1681	1683	of
O	1684	1692	patients
O	1693	1696	who
O	1697	1702	later
O	1703	1710	develop
O	1711	1716	overt
O	1717	1725	axillary
O	1726	1733	disease
O	1733	1734	.
